These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33160852)

  • 21. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
    Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Imaging and Clinically Relevant Features of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Hepatocellular Carcinoma.
    Huang X; Li Y; Long L
    Med Sci Monit; 2019 Nov; 25():8595-8601. PubMed ID: 31726461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.
    Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL
    HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.
    Kim TH; Kim H; Joo I; Lee JM
    Korean J Radiol; 2020 Oct; 21(10):1115-1125. PubMed ID: 32729276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
    J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
    Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
    Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
    Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
    Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
    Tischoff I; Tannapfel A
    Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.
    Liu G; Guo W; Wang H; Liu W; Lei L; Xie Q; Li X; Zou S; Wang P; Zhou H; Hu H
    Ann Palliat Med; 2021 Apr; 10(4):3673-3683. PubMed ID: 33691434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
    Hou GM; Jiang C; Du JP; Yuan KF
    Cancer Med; 2022 Jan; 11(2):317-331. PubMed ID: 34866356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.
    Sapisochin G; de Lope CR; Gastaca M; de Urbina JO; López-Andujar R; Palacios F; Ramos E; Fabregat J; Castroagudín JF; Varo E; Pons JA; Parrilla P; González-Diéguez ML; Rodriguez M; Otero A; Vazquez MA; Zozaya G; Herrero JI; Antolin GS; Perez B; Ciria R; Rufian S; Fundora Y; Ferron JA; Guiberteau A; Blanco G; Varona MA; Barrera MA; Suarez MA; Santoyo J; Bruix J; Charco R
    Ann Surg; 2014 May; 259(5):944-52. PubMed ID: 24441817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021).
    Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K
    J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis].
    Hu JY; Zhou HB; Liu WD; Zhang J; Hu HP; Liu J
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):511-515. PubMed ID: 31357776
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
    Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
    J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
    Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
    PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.
    Zhang F; Hu K; Tang B; Tian M; Lu S; Yuan J; Li M; Chen R; Ren Z; Shi Y; Yin X
    J Gastrointest Surg; 2021 Apr; 25(4):971-982. PubMed ID: 32350718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.